Literature DB >> 9738783

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.

M Lebwohl1, C Ellis, A Gottlieb, J Koo, G Krueger, K Linden, J Shupack, G Weinstein.   

Abstract

Cyclosporine has been in worldwide use for 15 years for patients who have undergone transplantation operations and is now being used to control inflammatory reactions in other organs (eg, joints, bowel, and skin). Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse events, drug interactions, interactions with other psoriasis treatments, and suggestions for cyclosporine's use in rotational therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738783     DOI: 10.1016/s0190-9622(98)70325-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

1.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

Review 2.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 3.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

Review 4.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Psoriasis treatment: traditional therapy.

Authors:  M Lebwohl; P T Ting; J Y M Koo
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

6.  Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study.

Authors:  W-Q Li; J-L Han; J E Manson; E B Rimm; K M Rexrode; G C Curhan; A A Qureshi
Journal:  Br J Dermatol       Date:  2012-04       Impact factor: 9.302

7.  Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy.

Authors:  Ramji Gupta
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

Review 8.  Ciclosporin use during pregnancy.

Authors:  Karolina Paziana; Magaly Del Monaco; Elyce Cardonick; Michael Moritz; Matthew Keller; Bruce Smith; Lisa Coscia; Vincent Armenti
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 9.  Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.

Authors:  Tim Nuttall; Douglas Reece; Elizabeth Roberts
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

Review 10.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.